Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Tango Therapeutics Inc. — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.55 (market cap $115.41B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 30.9× Tango Therapeutics Inc.'s market cap, and iShares 0 3 Month Treasury Bond ETF is more actively traded (24,687,195 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 51 Days and Tango Therapeutics Inc. for 0 Days on average.
| SGOV | TNGX | |
|---|---|---|
Market Cap | $115.41B | $3.74B |
Volume | 24,687,195 | 3,438,781 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $32.90 |
52-Week Low | $100.28 | $7.50 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52 with no price movement in the last 24 hours. The technical picture is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent corporate actions show consistent dividend distributions around $0.30-0.31 per share. The ETF faces headwinds from rising Treasury yields and institutional selling pressure.
The outlook for SGOV is challenged by the current bond market environment with yields hitting multi-year highs. While the ETF provides stable short-term Treasury exposure, investors face pressure from rising interest rates and institutional repositioning. Key risks include continued bond market volatility and shifting Federal Reserve policy expectations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
